vs
Side-by-side financial comparison of NorthEast Community Bancorp, Inc. (NECB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $26.4M, roughly 1.1× NorthEast Community Bancorp, Inc.). NorthEast Community Bancorp, Inc. runs the higher net margin — 40.9% vs -147.1%, a 188.0% gap on every dollar of revenue. On growth, NorthEast Community Bancorp, Inc. posted the faster year-over-year revenue change (3.9% vs -67.6%).
NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
NECB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.4M | $28.1M |
| Net Profit | $10.8M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 59.0% | -147.6% |
| Net Margin | 40.9% | -147.1% |
| Revenue YoY | 3.9% | -67.6% |
| Net Profit YoY | 5.8% | -182.8% |
| EPS (diluted) | $0.78 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.4M | $28.1M | ||
| Q3 25 | $27.0M | $32.5M | ||
| Q2 25 | $25.9M | $15.7M | ||
| Q1 25 | $25.5M | $8.0M | ||
| Q4 24 | $25.4M | $86.6M | ||
| Q3 24 | $27.6M | $2.1M | ||
| Q2 24 | $27.0M | $500.0K | ||
| Q1 24 | $25.5M | $0 |
| Q4 25 | $10.8M | $-41.3M | ||
| Q3 25 | $11.9M | $-51.2M | ||
| Q2 25 | $11.2M | $-44.9M | ||
| Q1 25 | $10.6M | $-33.9M | ||
| Q4 24 | $10.2M | $49.9M | ||
| Q3 24 | $12.7M | $-19.1M | ||
| Q2 24 | $12.8M | $-12.5M | ||
| Q1 24 | $11.4M | $-10.3M |
| Q4 25 | 59.0% | -147.6% | ||
| Q3 25 | 61.6% | -163.7% | ||
| Q2 25 | 59.5% | -302.9% | ||
| Q1 25 | 57.4% | -466.3% | ||
| Q4 24 | 57.0% | 54.5% | ||
| Q3 24 | 63.6% | -1051.6% | ||
| Q2 24 | 65.6% | -3068.0% | ||
| Q1 24 | 62.7% | — |
| Q4 25 | 40.9% | -147.1% | ||
| Q3 25 | 44.0% | -157.4% | ||
| Q2 25 | 43.1% | -285.6% | ||
| Q1 25 | 41.4% | -425.7% | ||
| Q4 24 | 40.1% | 57.7% | ||
| Q3 24 | 45.9% | -925.0% | ||
| Q2 24 | 47.5% | -2503.2% | ||
| Q1 24 | 44.5% | — |
| Q4 25 | $0.78 | $-0.41 | ||
| Q3 25 | $0.87 | $-0.52 | ||
| Q2 25 | $0.82 | $-0.46 | ||
| Q1 25 | $0.78 | $-0.35 | ||
| Q4 24 | $0.74 | $0.52 | ||
| Q3 24 | $0.95 | $-0.20 | ||
| Q2 24 | $0.97 | $-0.13 | ||
| Q1 24 | $0.86 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $81.2M | $245.0M |
| Total DebtLower is stronger | $70.0M | $96.4M |
| Stockholders' EquityBook value | $351.7M | $114.3M |
| Total Assets | $2.1B | $327.7M |
| Debt / EquityLower = less leverage | 0.20× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.2M | $245.0M | ||
| Q3 25 | $64.3M | $288.2M | ||
| Q2 25 | $59.4M | $240.1M | ||
| Q1 25 | $89.5M | $275.7M | ||
| Q4 24 | $78.3M | $314.0M | ||
| Q3 24 | $97.8M | $204.6M | ||
| Q2 24 | $113.9M | $218.7M | ||
| Q1 24 | $107.4M | $223.6M |
| Q4 25 | $70.0M | $96.4M | ||
| Q3 25 | $170.0M | $96.2M | ||
| Q2 25 | $135.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $47.0M | — | ||
| Q1 24 | $47.0M | — |
| Q4 25 | $351.7M | $114.3M | ||
| Q3 25 | $344.0M | $147.7M | ||
| Q2 25 | $336.7M | $192.3M | ||
| Q1 25 | $327.2M | $229.0M | ||
| Q4 24 | $318.3M | $256.8M | ||
| Q3 24 | $309.6M | $201.0M | ||
| Q2 24 | $300.0M | $215.2M | ||
| Q1 24 | $288.9M | $223.9M |
| Q4 25 | $2.1B | $327.7M | ||
| Q3 25 | $2.1B | $372.8M | ||
| Q2 25 | $2.0B | $313.5M | ||
| Q1 25 | $1.9B | $327.3M | ||
| Q4 24 | $2.0B | $351.2M | ||
| Q3 24 | $2.0B | $217.6M | ||
| Q2 24 | $1.9B | $222.0M | ||
| Q1 24 | $1.9B | $227.6M |
| Q4 25 | 0.20× | 0.84× | ||
| Q3 25 | 0.49× | 0.65× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $52.6M | $-43.5M |
| Free Cash FlowOCF − Capex | $50.8M | — |
| FCF MarginFCF / Revenue | 192.3% | — |
| Capex IntensityCapex / Revenue | 6.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $89.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.6M | $-43.5M | ||
| Q3 25 | $14.1M | $-47.0M | ||
| Q2 25 | $15.6M | $-39.6M | ||
| Q1 25 | $10.9M | $-40.7M | ||
| Q4 24 | $48.7M | $42.0M | ||
| Q3 24 | $14.4M | $-14.5M | ||
| Q2 24 | $11.1M | $-7.3M | ||
| Q1 24 | $12.9M | $-6.7M |
| Q4 25 | $50.8M | — | ||
| Q3 25 | $13.6M | $-47.2M | ||
| Q2 25 | $14.9M | $-39.6M | ||
| Q1 25 | $10.6M | $-40.8M | ||
| Q4 24 | $48.2M | $41.7M | ||
| Q3 24 | $14.2M | $-14.6M | ||
| Q2 24 | $11.0M | $-7.3M | ||
| Q1 24 | $12.8M | $-6.8M |
| Q4 25 | 192.3% | — | ||
| Q3 25 | 50.5% | -145.4% | ||
| Q2 25 | 57.3% | -252.2% | ||
| Q1 25 | 41.4% | -512.1% | ||
| Q4 24 | 189.3% | 48.2% | ||
| Q3 24 | 51.5% | -706.3% | ||
| Q2 24 | 40.8% | -1463.4% | ||
| Q1 24 | 50.3% | — |
| Q4 25 | 6.6% | 0.0% | ||
| Q3 25 | 1.6% | 0.6% | ||
| Q2 25 | 2.9% | 0.3% | ||
| Q1 25 | 1.5% | 1.1% | ||
| Q4 24 | 2.0% | 0.3% | ||
| Q3 24 | 0.6% | 6.8% | ||
| Q2 24 | 0.5% | 7.6% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 4.86× | — | ||
| Q3 25 | 1.18× | — | ||
| Q2 25 | 1.40× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 4.77× | 0.84× | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 1.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NECB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
